

## Experimental approach to advanced prostate cancer

Poster Session 56

Sunday, 26 March  
15:45 - 17:15

**Location:** Room Stockholm, North Hall (Level 1)

**Chairs:** C. Bevan, London (GB)  
P. Sooriakumaran, London (GB)  
C. Thomas, Mainz (DE)

### Aims and objectives of this session

Recent research has revealed several novel targets in prostate cancer. However, a single therapy approach will likely not be efficient in improving patient survival. For this reason, systemic pharmacology approaches have been developed in order to provide a scientific basis for novel therapies. The session will also address key issues of drug delivery in prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

16:08 - 16:18

### New approaches to overcome endocrine therapy resistance in prostate cancer

P. Sooriakumaran, London (GB)

\*746

### Identification and characterization of selective androgen receptor degraders (SARDs) for the treatment of enzalutamide unresponsive and/or resistant prostate cancer

By: [Getzenberg R.](#)<sup>1</sup>, Ponnusamy S.<sup>2</sup>, Thiyagarajan T.<sup>3</sup>, Hwang D-J.<sup>3</sup>, He Y.<sup>3</sup>, McEwan I.<sup>4</sup>, Watt C.<sup>4</sup>, Moldoveanu T.<sup>5</sup>, Miller D.<sup>6</sup>, Narayanan R.<sup>2</sup>

**Institutes:**<sup>1</sup>Gtx Inc, Dept. of Prostate Cancer, Memphis, United States of America, <sup>2</sup>University of Tennessee Health Science Center, Dept. of Medicine, Memphis, United States of America, <sup>3</sup>University of Tennessee Health Science Center, Dept. of Pharmaceutical Sciences, Memphis, United States of America, <sup>4</sup>School of Medicine, Institute of Medical Sciences, Aberdeen, United Kingdom, <sup>5</sup>St. Jude's Children's Research Hospital, Dept. of Structural Biology, Memphis, United States of America, <sup>6</sup>University of Tennessee Health Science Center, Pharmaceutical Sciences, Memphis, United States of America

747

### Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201

By: [Borgmann H.](#), Ozistanbullu D., Beraldi E., Dalal K., Fazli L., Gleave M.

**Institutes:**Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

748

### Targeting androgen receptor variants by niclosamide overcomes resistance to abiraterone and enzalutamide

By: Liu C., Lou W., Pan C-X., Evans C., [Gao A.](#)

**Institutes:**University of California Davis, Dept. of Urology, Sacramento, United States of America

749

### The STAT3 inhibitor galiellalactone prevents prostate cancer cell induced generation of myeloid derived suppressor cells from monocytes ex vivo

By: [Hellsten R.](#)<sup>1</sup>, Leandersson K.<sup>2</sup>, Johansson M.<sup>3</sup>, Bjartell A.<sup>1</sup>

**Institutes:**<sup>1</sup>Division of Urological Cancers, Dept. of Translational Medicine, Lund University, Malmö, Sweden, <sup>2</sup>Cancer Immunology, Dept. of Translational Medicine, Lund University, Malmö, Sweden, <sup>3</sup>Glactone Pharma AB, Helsingborg, Sweden

750

### The multi-kinase inhibitor EC-70124 delivers a double-hit to prostate cancer stem cells interfering with both STAT3 and NF-κB signaling

**By:** Civenni G.<sup>1</sup>, Shinde D.<sup>1</sup>, Zoma M.<sup>1</sup>, Albino D.<sup>1</sup>, Costales P.<sup>2</sup>, Moris F.<sup>2</sup>, Carbone G.<sup>1</sup>, Catapano C.<sup>1</sup>  
**Institutes:**<sup>1</sup>IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, <sup>2</sup>Edificio Científico Tecnológico, EntreChem, EntreChem, Oviedo, Spain

751 **Dopamine hydrochloride relative nanoparticles in the treatment of prostate cancer**

**By:** Zhang C., Zhao X., Lin T., Guo H.  
**Institutes:**Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

752 **ALK1Fc suppresses tumor growth by impairing proliferation of human prostate cancer cells in vitro and in vivo**

**By:** Astrologo L.<sup>1</sup>, Zoni E.<sup>1</sup>, Karkampouna S.<sup>1</sup>, Gray P.<sup>2</sup>, Klima I.<sup>1</sup>, Grosjean J.<sup>1</sup>, Goumans M.J.<sup>2</sup>, Hawinkels L.<sup>2</sup>, Van Der Pluijm G.<sup>3</sup>, Ten Dijke P.<sup>2</sup>, Spahn M.<sup>4</sup>, Thalmann G.<sup>4</sup>, Kruithof-De Julio M.<sup>1</sup>  
**Institutes:**<sup>1</sup>Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, <sup>2</sup>Leiden University Medical Center, Dept. of Molecular Cell Biology, Leiden, The Netherlands, <sup>3</sup>Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, <sup>4</sup>University Hospital Bern, Dept. of Urology, Bern, Switzerland

753 **A tale of tails: A novel approach to immunotherapy of prostate cancer**

**By:** Galustian C.<sup>1</sup>, Smolarek D.<sup>1</sup>, Sakellariou C.<sup>1</sup>, Elhage O.<sup>1</sup>, Smith R.<sup>1</sup>, Dasgupta P.<sup>2</sup>  
**Institutes:**<sup>1</sup>Kings College London, Dept. of Innate Immunity, London, United Kingdom, <sup>2</sup>Kings College London, Dept. of Innate Immunity and the Urology Centre, London, United Kingdom

754 **Systems pharmacology and quantitative proteomics for developing targeted triple therapy**

**By:** Ebhardt H.A.<sup>1</sup>, Root A.<sup>2</sup>, Beizaei A.<sup>1</sup>, Liu Y.<sup>3</sup>, Gauthier N.<sup>4</sup>, Sander C.<sup>4</sup>, Aebersold R.<sup>3</sup>  
**Institutes:**<sup>1</sup>University College Dublin, Systems Biology Ireland, Dublin, Ireland, <sup>2</sup>Memorial Sloan-Kettering Cancer Center, Weill Cornell Graduate School of Medical Sciences, New York City, United States of America, <sup>3</sup>ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland, <sup>4</sup>Dana-Farber Cancer Institute, CBio Center At Dana-Farber, Boston, United States of America

755 **Transdermal delivery of leuprolide acetate with chitosan microneedles: A promising tool for androgen deprivation therapy**

**By:** Tsai Y-S.<sup>1</sup>, Chen M-Y.<sup>2</sup>, Lan S-K.<sup>3</sup>, Tsai H-T.<sup>4</sup>, Chen M-C.<sup>5</sup>, Tzai T-S.<sup>6</sup>  
**Institutes:**<sup>1</sup>National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, <sup>2</sup>Madou SinLau Hospital, Dept. of Urology, Tainan, Taiwan, <sup>3</sup>Dalin Tzu-Chi Hospital, Dept. of Urology, Tainan, Taiwan, <sup>4</sup>National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan, <sup>5</sup>National Cheng-Kung University, Dept. of Chemical Engineering, Tainan, Taiwan, <sup>6</sup>Tainan An-Nan Hospital, Dept. of Urology, Tainan, Taiwan

756 **Co-treatment with L-methadone increases the efficacy of cytostatic drugs in prostate cancer cells**

**By:** Stadlbauer B.<sup>1</sup>, Kozian D.<sup>2</sup>, Stief C.<sup>1</sup>, Buchner A.<sup>1</sup>  
**Institutes:**<sup>1</sup>Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, <sup>2</sup>Sanofi-Aventis GmbH, Research Department, Frankfurt, Germany

757 **SEMA3C drives cancer growth and treatment resistance via cognate ligand-independent activation of multiple receptor tyrosine kinases**

**By:** Takeuchi A.<sup>1</sup>, Masaki S.<sup>1</sup>, Peacock J.<sup>2</sup>, Eto M.<sup>1</sup>, Martin E G.<sup>2</sup>, Ong C.<sup>2</sup>  
**Institutes:**<sup>1</sup>Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, <sup>2</sup>University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada